Andrey Boldin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrey Boldin has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Kseniya M. Shestakova
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Российская Федерация
2 shared publications - Svetlana Alexandrovna Appolonova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Yuriy Nikitich Belenkov
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Alex Brito
School of Nutrition and Dietetics, Faculty of Rehabilitation and Quality of Life Sciences, Universidad San Sebastián, Patagonia Campus, Lago Panguipulli 1390, Puerto Montt, Chile
1 shared publication - Alexey V. Kukharenko
Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow Medical University, 8/2 Trubetskaya, 119991 Moscow, Russia
1 shared publication - Anastasiia V. Kakotkina
Hospital Therapy No. 1 Department, N.V. Sklifosovskiy Institute of Clinical Medicine, I.M. Sechenov First Moscow Medical University (Sechenov University), 119991 Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 20 December 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (11) , 908-919
Changes in the metabolomic profile of blood plasma in patients with lymphoma during polychemotherapy
Background. Metabolomics studies in oncology provide a deeper understanding of the biochemical processes associated with tumor growth and the body's response to treatment. In patients with lymphoma, systemic metabolic changes remain poorly understood despite their high clinical significance. Aim. To evaluate changes in the metabolomic profile of blood plasma in patients with lymphoma at various stages of polychemotherapy (PCT) and compare them to those of healthy volunteers. Materials and methods. The study included 18 patients with lymphoma from whom blood was collected before treatment and after the first and third courses of PCT. The control group included 30 healthy volunteers. The analysis was performed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) and included measurements of amino acids, tryptophan and arginine derivatives, and acylcarnitines. Statistical processing was performed using analysis of variance and principal component analysis. Results. Prior to therapy, patients showed characteristic metabolic disorders: activation of the kynurenine pathway of tryptophan metabolism, a decrease in arginine, and an increase in its methylated derivatives, as well as shifts in the amino acid and acylcarnitine profiles. During PCT, partial normalization of these indicators was observed, especially for the serotonin-melatonin cascade and kynurenine metabolites. Conclusion. Metabolomics analysis revealed characteristic biochemical changes in patients with lymphoma and their changes over time during treatment. The data obtained emphasize the potential of metabolomics as a tool for monitoring treatment effectiveness and patient condition in oncology.
- 20 December 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (11) , 908-919
Open AccessChanges in the metabolomic profile of blood plasma in patients with lymphoma during polychemotherapy
Background. Metabolomics studies in oncology provide a deeper understanding of the biochemical processes associated with tumor growth and the body's response to treatment. In patients with lymphoma, systemic metabolic changes remain poorly understood despite their high clinical significance. Aim. To evaluate changes in the metabolomic profile of blood plasma in patients with lymphoma at various stages of polychemotherapy (PCT) and compare them to those of healthy volunteers. Materials and methods. The study included 18 patients with lymphoma from whom blood was collected before treatment and after the first and third courses of PCT. The control group included 30 healthy volunteers. The analysis was performed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) and included measurements of amino acids, tryptophan and arginine derivatives, and acylcarnitines. Statistical processing was performed using analysis of variance and principal component analysis. Results. Prior to therapy, patients showed characteristic metabolic disorders: activation of the kynurenine pathway of tryptophan metabolism, a decrease in arginine, and an increase in its methylated derivatives, as well as shifts in the amino acid and acylcarnitine profiles. During PCT, partial normalization of these indicators was observed, especially for the serotonin-melatonin cascade and kynurenine metabolites. Conclusion. Metabolomics analysis revealed characteristic biochemical changes in patients with lymphoma and their changes over time during treatment. The data obtained emphasize the potential of metabolomics as a tool for monitoring treatment effectiveness and patient condition in oncology.
- Open Access
- 27 July 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (3) , 230-239
Plasma branched-chain amino acid concentrations in individuals without cardiovascular diseases versus patients diagnosed with hypertension and coronary artery disease
Aim. Branched-chain amino acids (BCAAs) have been postulated as potential indicators of cardiovascular risk. The objective of this study was to explore the relationship between plasma BCAAs and different stages of cardiovascular disorders.Material and methods. In our cross-sectional study, plasma BCAAs (valine, leucine and isoleucine) in individuals without cardiovascular diseases (CVDs) (nonCVD group, total n=27, with n=16 healthy, but with metabolic disorders) were compared to patients diagnosed with CVDs [CVD group, total n=109, being n=61 hypertension (n=31 with signs of beginning of myocardial remodeling) and n=48 patients with coronary artery disease (CAD)].Results. The plasma concentration of BCAAs was significantly higher in the group of patients with cardiovascular disease compared with the healthy group (pConclusion. BCAAs concentrations are elevated with higher severity of the cardiovascular disorder and exhibit potential as early independent indicators of coronary artery disease.
- 27 July 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (3) , 230-239
Open AccessPlasma branched-chain amino acid concentrations in individuals without cardiovascular diseases versus patients diagnosed with hypertension and coronary artery disease
Aim. Branched-chain amino acids (BCAAs) have been postulated as potential indicators of cardiovascular risk. The objective of this study was to explore the relationship between plasma BCAAs and different stages of cardiovascular disorders.Material and methods. In our cross-sectional study, plasma BCAAs (valine, leucine and isoleucine) in individuals without cardiovascular diseases (CVDs) (nonCVD group, total n=27, with n=16 healthy, but with metabolic disorders) were compared to patients diagnosed with CVDs [CVD group, total n=109, being n=61 hypertension (n=31 with signs of beginning of myocardial remodeling) and n=48 patients with coronary artery disease (CAD)].Results. The plasma concentration of BCAAs was significantly higher in the group of patients with cardiovascular disease compared with the healthy group (pConclusion. BCAAs concentrations are elevated with higher severity of the cardiovascular disorder and exhibit potential as early independent indicators of coronary artery disease.